Your browser doesn't support javascript.
loading
Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study.
Luo, Cheng; Luo, Shuhang; Wusimanjiang, Wumier; Wang, Zongren; Liu, Ping; Wang, Bin; Yuan, Dan; Lin, Hao; Xu, Abai; Deng, Nan; Wu, Kaihui; Zhu, Xuejin; Xu, Peng; Chen, Junxing; Huang, Bin.
Afiliação
  • Luo C; Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China.
  • Luo S; Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China.
  • Wusimanjiang W; Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China.
  • Wang Z; Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China.
  • Liu P; Department of Urology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Wang B; Department of Urology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
  • Yuan D; Department of Urology, Jiangmen Central Hospital, Jiangmen, China.
  • Lin H; Department of Urology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China.
  • Xu A; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
  • Deng N; Department of Urology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Wu K; Department of Urology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Zhu X; Department of Urology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
  • Xu P; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
  • Chen J; Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China. chenjunx@mail.sysu.edu.cn.
  • Huang B; Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China. huangb48@mail.sysu.edu.cn.
Clin Transl Oncol ; 26(7): 1759-1767, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38472556
ABSTRACT

PURPOSE:

To retrospectively evaluate the tislelizumab-based chemoimmunotherapy combined with gemcitabine/cisplatin for bladder-sparing in patients with muscle-invasive bladder cancer (MIBC).

METHODS:

Forty-five patients who received bladder-sparing treatment or radical cystectomy (RC) for MIBC (cT2-T4a, NxM0) were retrospectively enrolled. All patients received maximal transurethral resection of bladder tumor (mTURBT), followed by four cycles of chemo-immunotherapy with tislelizumab (PD-L1 inhibitor), gemcitabine, and cisplatin. Clinical efficacy was evaluated to compare the benefit of bladder-sparing treatment on clinical CR (cCR) and RC for non-cCR patients. The primary outcomes were bladder intact disease-free survival (BIDFS) and overall survival (OS), and the secondary outcomes were adverse effects. The PD-L1 status and molecular subtypes of tumors were analyzed.

RESULTS:

The overall survival rate was 88.8% (95%CI 79.6%, 98.0%) at 12 months, 85.7% (95%CI 74.9%, 96.5%) at 18 months, and 66.6% (95%CI 45.2%, 88.0%) at 24 months. Twenty-nine patients (64.4%) achieved cCR and their OS rate was 96.6% (95%CI 89.9%, 100%). Sixteen patients were in the non-cCR group, and their OS rate was 75.0% (95%CI 53.8%, 96.2%) at 12 months, 65.6% (95%CI 40.3%, 90.9%) at 18 months, and 52.5% (95%CI 21.9%, 83.1%) at 24 months. The BIDFS rate for patients who received bladder-sparing treatment was 96.0% (95%CI 88.4%, 100%) from 12 to 24 months. Four patients (8.8%) were PD-L1 positive and 41 patients (91.2%) were PD-L1 negative.

CONCLUSIONS:

Our retrospective study of patients with MIBC suggests that tislelizumab-based neoadjuvant therapy was a safe and effective bladder-sparing treatment.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Protocolos de Quimioterapia Combinada Antineoplásica / Cistectomia / Cisplatino / Desoxicitidina / Anticorpos Monoclonais Humanizados / Gencitabina / Invasividade Neoplásica Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Protocolos de Quimioterapia Combinada Antineoplásica / Cistectomia / Cisplatino / Desoxicitidina / Anticorpos Monoclonais Humanizados / Gencitabina / Invasividade Neoplásica Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Itália